Carlos Jogi Imaeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carlos Jogi Imaeda has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- André Miotto
Universidade Federal de São Paulo, Brasil; Hospital São Paulo, Brasil
1 shared publication - Fabio José Haddad
Hospital Beneficência Portuguesa de São Paulo, Brasil
1 shared publication - Jaquelina Sonoe Ota Arakaki
UNIFESP
1 shared publication - João Aléssio Juliano Perfeito
Universidade Federal de São Paulo, Brasil; Hospital São Paulo, Brasil
1 shared publication - Marcel Sandrini
Hospital Beneficência Portuguesa, Brazil
1 shared publication - Maria Alenita de Oliveira
Universidade Federal da Paraíba João Pessoa
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 53
Estenose traqueal pós intubação: análise de 250 casos operados e o legado do professor Vicente Forte
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 53
Open AccessEstenose traqueal pós intubação: análise de 250 casos operados e o legado do professor Vicente Forte
- Open Access
- 28 May 2021
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 139 (3) , 293-300
The role of the surgeon in treating patients with lung cancer. An updating article
Lung cancer is a type of neoplasia with one of the highest incidences worldwide and is the largest cause of mortality due to cancer in the world today. It is classified according to its histological and biological characteristics, which will determine its treatment and prognosis. Non-small cell lung cancer accounts for 85% of the cases, and these are the cases that surgeons mostly deal with. Small cell lung cancer accounts for the remaining 15%. Surgery is the main method for treating early stage lung cancer, and lobectomy is the preferred procedure for treating primary lung cancer, while sublobar resection is an alternative for patients with poor reserve or with very small tumors. Surgeons need to be trained to use the resources and techniques available for lung resection, including less invasive approaches such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS), and need to be familiar with new oncological approaches, including curative, adjuvant or palliative treatments for patients with lung cancer.
- 28 May 2021
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 139 (3) , 293-300
Open AccessThe role of the surgeon in treating patients with lung cancer. An updating article
Lung cancer is a type of neoplasia with one of the highest incidences worldwide and is the largest cause of mortality due to cancer in the world today. It is classified according to its histological and biological characteristics, which will determine its treatment and prognosis. Non-small cell lung cancer accounts for 85% of the cases, and these are the cases that surgeons mostly deal with. Small cell lung cancer accounts for the remaining 15%. Surgery is the main method for treating early stage lung cancer, and lobectomy is the preferred procedure for treating primary lung cancer, while sublobar resection is an alternative for patients with poor reserve or with very small tumors. Surgeons need to be trained to use the resources and techniques available for lung resection, including less invasive approaches such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS), and need to be familiar with new oncological approaches, including curative, adjuvant or palliative treatments for patients with lung cancer.